Altimmune (ALT) closed at $1.41 on November 19, 2026, up 1.4% from the previous close, on volume of 4,087,386 shares (30-day average 3,788,886).
Data as of November 19, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Call Spread | 15-Jan-272.5 : 3 C | 1,898 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Globe Newswire (Thu, 19-Nov 8:00 AM ET)
Altimmune (ALT) Gets a Buy from Barclays
TipRanks (Wed, 18-Nov 4:35 AM ET)
Altimmune Buy Rating Maintained with $20 Price Target as Pemvidutide Shows Promise in AUD and MASH
TipRanks (Tue, 17-Nov 6:35 AM ET)
Altimmune Earnings Call Highlights Pemvidutide Momentum
TipRanks (Sun, 15-Nov 12:01 AM ET)
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Globe Newswire (Thu, 12-Nov 7:15 AM ET)
Globe Newswire (Mon, 9-Nov 12:30 PM ET)
Globe Newswire (Thu, 5-Nov 10:00 AM ET)
Globe Newswire (Thu, 5-Nov 9:20 AM ET)
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Altimmune trades on the NASDAQ stock market under the symbol ALT.
As of November 20, 2026, ALT stock price declined to $1.32 with 3,118,455 million shares trading.
ALT has a beta of 1.57, meaning it tends to be more sensitive to market movements. ALT has a correlation of 0.07 to the broad based SPY ETF.
ALT has a market cap of $256.86 million. This is considered a Small Cap stock.
Last quarter Altimmune reported $0 in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-1,400 and missed earnings estimates by -$.01.
In the last 3 years, ALT traded as high as $14.84 and as low as $1.32.
The top ETF exchange traded funds that ALT belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
ALT has underperformed the market in the last year with a price return of -71.2% while the SPY ETF gained +5.4%. ALT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -57.7% and -33.0%, respectively, while the SPY returned -9.9% and -5.7%, respectively.
ALT support price is $1.34 and resistance is $1.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALT shares will trade within this expected range on the day.